Objective: To evaluate the effect of radial optic neurotomy on visual acuity (VA) and foveal thickness in patients with hemicentral retinal vein occlusion.
H
EMICENTRAL RETINAL VEIN occlusion (HCRVO), first described by Hayreh and Hayreh 1 as a clinical variant of central retinal vein occlusion (CRVO), is the least frequently occurring retinal vein occlusion. According to those authors, a 2-trunked central retinal vein in the anterior part of the optic nerve may persist in a percentage of human beings as an anatomic variant. 2, 3 One of the 2 trunks, as in CRVO, may become occluded to produce an HCRVO, a distinct entity clinically and pathogenetically related to CRVO and unrelated to branch retinal vein occlusion.
Like other authors, 1,3-5 we differentiate HCRVO from hemispheric retinal vein occlusion. In hemispheric retinal vein occlusion, the obstruction is produced in an arteriovenous crossing close to or at the optic disc; for this reason it is considered a variant of branch retinal vein occlusion. The clinical findings of HCRVO resemble those observed in CRVO confined to half of the retinal extension, and its management has been similar to that of CRVO. Opremcak et al 6 described radial optic neurotomy, that is, radial surgical section of the optic nerve head on the nasal border near the central retinal vein as well as the adjacent retina and peripapillary sclera, as a way to release proposed pressure on the scleral canal. It has been reported [7] [8] [9] [10] that radial optic neurotomy also induces new retinochoroidal shunts at the site of the neurotomy that drain the retinal circulation to the choroid and accelerate the resolution of the retinal edema in cases of CRVO. Considering the similar nature of HCRVO and CRVO, the purpose of our study was to determine the visual results in patients with HCRVO and a preoperative visual acuity (VA) of 20/60 or worse treated with radial optic neurotomy and to determine the effects of radial optic neurotomy on macular edema.
METHODS
A prospective, noncontrolled, interventional study was designed to treat 13 of 20 patients with clinical and angiographic characteristics of HCRVO and decreased VA. The vascular pattern and arteriovenous crossings were carefully examined at the optic disc level to differentiate HCRVOs from hemispheric retinal vein occlusions. Twenty HCRVOs were diagnosed of a total of 232 retinal vein occlusions (92 CRVOs, 105 branch retinal vein occlusions, 20 HCRVOs, and 15 hemispheric retinal vein occlusions).
One of the inclusion criteria was a VA of 20/60 or worse owing to macular edema secondary to HCRVO within 3 months of onset. The 7 patients with HCRVO and a visual acuity better than 20/60 were observed but excluded from the study. Exclusion criteria were previous laser photocoagulation and vitreous hemorrhage or retinal neovascularization secondary to HCRVO. Patients were fully informed of all aspects of the procedure and all provided written informed consent. Ethics committee approval was obtained for this study.
Preoperative recorded data included patient age, sex, and race; affected eye; bilaterality; time from onset of HCRVO; refraction; and measurement of VA using the Early Treatment Diabetic Retinopathy Study chart. Also recorded were risk factors, such as hypertension, open-angle glaucoma, hyperlipidemia, primary antiphospholipid antibody syndrome, and other thrombophilic factors.
All 13 eyes underwent indirect ophthalmoscopy and slitlamp examination, including biomicroscopy of the vitreous and retina. Fundus photography and fluorescein angiography were also performed in each patient. The type of CRVO was not classified as perfused or nonperfused, as in the Central Vein Occlusion Study, because a substantial number of them were indeterminate owing to intraretinal hemorrhages that prevented correct interpretation of the angiographic findings.
Optical coherence tomography (OCT3; Carl Zeiss Meditec, Humphrey Division, Dublin, Calif ) was performed in all patients to measure foveal thickness, and the best-corrected VA (BCVA) was obtained at the same time in all eyes within 1 week prior to surgery. Optical coherence tomography and BCVA were measured at 1, 3, and 6 months postoperatively. Final VA was considered to be that measured at the 6-month follow-up visit.
Patients were fully informed of all relevant aspects of the procedure. All procedures were performed by 1 surgeon (J.G.A.). A 2-port pars plana vitrectomy was performed in all patients. One of the ports was used for a light with infusion (Alcon Laboratories, Inc, Fort Worth, Tex) and the other for the active instruments. If the cortical vitreous was adhering to the posterior pole, the posterior hyaloid was dissected from the retina using a vitreous probe or a silicone-tipped cannula, under active aspiration. The dissection began over the optic disc or at the temporal vascular arcade. A standard microvitreoretinal blade was used to perform the radial optic neurotomy (a radial cut was made on the nasal aspect of the disc of the corresponding hemiretina) under an intraocular pressure of 40 mm Hg. The microvitreoretinal blade was introduced in all cases through the nasal sclerotomy to achieve a more perpendicular neurotomy. Intraocular pressure was increased, in case of bleeding, to 80 mm Hg.
The following postoperative parameters were evaluated: changes in BCVA, decreased macular edema measured clinically and by OCT, decreased or resolved intraretinal hemorrhages, incidence of chorioretinal anastomosis, and incidence of iris neovessels or neovascular glaucoma. Results were calculated with nonparametric statistical methods. The relationship between preoperative and postoperative VA and macular thickness (measured with OCT) was calculated using the Spearman rank correlation coefficient and scatterplot graphs. PϽ.05 was considered statistically significant.
RESULTS
The 13 patients (8 men and 5 women) ranged in age from 41 to 80 years (median age, 69 years). Follow-up ranged from 6 to 12 months postoperatively (mean, 8 months). Preoperative BCVA ranged from 20/400 to 20/60 (median, 20/100). Preoperative foveal thickness measured by OCT varied from 364 to 971 µm (median, 558 µm).
Each patient had a symptomatic decrease in VA in the affected eye due to HCRVO of less than 12 weeksЈ duration (range, 2-11 weeks; median, 6 weeks from onset). Of the 13 patients, systemic hypertension was present in 9 (69.2%), primary open-angle glaucoma in 4 (30.8%), diabetes mellitus in 6 (30.8%), and antiphospholipid antibody syndrome in 1 (7.7%). Only 2 patients had no systemic disease. In 1 patient (patient 6) (7.7%), a CRVO in the fellow eye caused neovascular glaucoma, and 5 patients (patients 2, 4, 8, 11, and 12) (38.5%) had a branch retinal vein occlusion.
Patient demographic data are given in the Table. Hemicentral retinal vein occlusion was superior in 6 patients and inferior in 7 patients. Slight vitreous hemorrhage was observed in the early postoperative period in 1 (7.7%) of the 13 patients but cleared spontaneously in 3 weeks. A small subretinal hemorrhage was present at the radial optic neurotomy site in 2 patients (15.3%). After surgery, nuclear sclerosis developed in 9 patients (69%) and retinal pigment epithelial changes were observed in 3 patients (23%). Clinical improvement in macular edema and hemorrhages was observed in all of the patients (Figure 1 and Figure 2) .
Postoperative VA ranged from 20/100 to 20/25 (median, 20/50). The difference between preoperative and postoperative VAs was statistically significant (PϽ.01). Nine patients (69%) had improved BCVA with 2 or more Snellen lines of vision gained, and 4 patients (30.8%) demonstrated improvement of 4 or more Snellen lines. No patient had a postoperative decrease in VA. In 3 patients (patients 5, 9, and 12), final VA remained unchanged because of retinal pigment epithelium atrophy secondary to chronic macular edema or subretinal hemorrhage.
Postoperative macular edema ranged from 171 to 390 µm (median, 252 µm). Median decrease was 306 µm. Visual acuity recovery was statistically related to the decrease in macular edema (P = .02; = −0.62) (Figure 3) .
In 6 patients (46.1%), postoperative retinochoroidal shunts developed at the radial optic neurotomy site. The group of patients with retinochoroidal shunts showed a tendency to achieve a better mean final VA than did those in whom no collateral vessels were observed (mean final VA of 20/40 in the group with collateral vessels vs a VA of 20/50 in the group without collateral vessels), although this difference was not statistically significant (PϾ.05).
Retinal neovascularization developed in 1 patient (patient 3) and was managed with panretinal laser photocoagulation in the corresponding hemiretina. No iris neovascularization was observed by the end of follow-up. out an accompanying vein, which appears in the third month of intrauterine life as 2 vascular channels at either side of the artery. Usually 1 of the 2 venous channels disappears before birth, leaving the central retinal vein as 1 trunk. However, the embryonic pattern may persist, 2 and in 20% of the cases in which it does, HCRVO may occur as a result of occlusion of 1 of these 2 trunks.
As reported by others, 5 risk factors observed in our patients included hypertension, primary open-angle glaucoma, and diabetes mellitus. These risk factors are also associated with CRVO. In our series, 4 (30%) of 13 patients were diagnosed as having primary open-angle glaucoma, values similar to those recently reported in the literature. 13 Only 1 patient had altered thrombophilia test results, which corresponded to primary antiphospholipid antibody syndrome.
The proposed management of HCRVO has been similar to that for CRVO. Panretinal photocoagulation in their series of patients with HCRVO, observed stabilization of initial VA in most patients (61%), improved VA in 22%, and worsening of initial VA in 17% after a mean follow-up of 15 months. Moreover, a mean of 67% of patients exhibited chronic cystoid changes in the macula, and in patients in whom macular edema resolved, it did so during the first 3 to 5 months. Chopdar 3,15 observed similar visual results: of 11 patients studied, 7 (63.6%) maintained VA as at the first examination and 4 patients (36.3%) gained 1 or more Snellen lines of VA. Mean follow-up was 7.8 months (range, 2-18 months), and in 50% of patients, follow-up was less than 6 months. Initial and final VA in that series of patients did not vary significantly, and in one third of these patients the initial VA was better than 20/60.
In our series, radial optic neurotomy was performed in an attempt to achieve an effect similar to that observed in CRVO. Macular thickness as measured using OCT clearly improved in all patients, and VA increased by 2 or more Snellen lines in 69% of the patients and by 4 or more Snellen lines in 30.8% after radial optic neurotomy. In most patients (70%), venous outflow improved in the postoperative period; the remainder were those with longer duration of symptoms (Ն60 days). Radial optic neurotomy induced chorioretinal anastomosis in 41% of the patients after a mean of 6 weeks; this effect had been previously observed in pilot studies using this procedure in patients with CRVO. [7] [8] [9] [10] To our knowledge, there is no report in the literature on the management of macular edema secondary to HCRVO with radial optic neurotomy, apart from an isolated case reported by Weizer et al. 16 We believe that improvement in our patients may have occurred by means of different mechanisms. First, proposed mechanical pressure exerted on the hemicentral retinal vein in the optic nerve was relieved. Second, we used vitrectomy and posterior hyaloid peeling, which have experimentally proved to decrease macular edema 11 ; most probably, the exchange between the retina and vitreous cavity after vitrectomy is easier and helps decrease macular edema. Third, new retinochoroidal shunts developed in 6 patients at the radial optic neurotomy site, creating a new venous outflow pathway. We believe the collateral vessels formed after neurotomy appear earlier and are more active in draining edema and hemorrhages than are those that appear spontaneously (this has been observed by several authors who have managed CRVO with radial optic neurotomy [7] [8] [9] [10] ) or those created after laser application.
14 In addition, their location close to the optic nerve renders them more effective. The time of appearance of spontaneous cilioretinal collateral vessels is not well established, ranging from 2 to 25 months (mean, 6.7 months), according to Fuller et al 17 in patients with CRVO, a duration much longer than that induced by radial optic neurotomy, which is about 6 weeks. Thus, we strongly believe that the anastomoses in these cases were directly related to radial optic neurotomy. In our study, patients in whom new retinochoroidal collateral vessels were observed showed a tendency to achieve better final visual outcome.
Intravitreal triamcinolone acetonide, which acts by down-regulating the vascular endothelial growth factor, would probably help to reduce macular edema during the immediate postoperative period and would be well associated with surgery because it addresses another of the mechanisms involved in HCRVO. 18, 19 We observed no choroidal neovascularization in the neurotomy site, peripapillary retinal detachment, or central artery occlusion, as previously reported in radial optic neurotomy for treatment of CRVO. 20, 21 That the technique proved useful in HCRVO, as it previously had in CRVO, and that newly formed retinochoroidal anastomoses appeared at the neurotomy site support the theory of a common pathogenesis of these 2 types of retinal vein occlusions.
This study has 2 main limitations: the small number of patients and the lack of a comparison group. However, considering the low prevalence of this disease, it can be deemed significant in that only 20 HCRVOs were diagnosed in a considerable series of retinal vein occlusions, and among those, only the patients with the worst initial VA were included. Thus, without a randomized, controlled trial and more patients, the efficacy and safety of this procedure cannot be proved.
As these preliminary data suggest, radial optic neurotomy seems to be a potential treatment for selected HCRVOs, which seem to have better evolution than the natural history, probably owing to the more rapid appearance of retinochorioretinal collateral vessels, which promote faster resolution of macular edema and may protect against neovascular complications. 
